14 results
8-K
EX-99.1
COYA
Coya Therapeutics Inc
20 May 24
Coya Therapeutics Announces $5 Million Strategic
5:00pm
the development of drugs for Alzheimer’s, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF’s leadership
8-K
EX-99.1
COYA
Coya Therapeutics Inc
21 Aug 23
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, joins Coya’s Board of Directors
5:01pm
clinical difference in patients’ lives suffering from difficult to treat neurodegenerative diseases, an experienced leadership team that I believe can
DEF 14A
COYA
Coya Therapeutics Inc
19 May 23
Definitive proxy
4:31pm
Leadership Structure and Role in Risk Oversight
Evaluations of the Board of Directors
Stockholder Communications
Code of Business Conduct and Ethics
Anti … leadership roles at Aisling Capital, a private investment firm, from 2006 to 2017, serving as its Managing Partner from 2014 to 2017. Dr. Goldstein
8-K
EX-99.1
COYA
Coya Therapeutics Inc
10 May 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
7:11am
Berman, Ph.D., Chief Executive Officer of Coya. “Subsequent to quarter end, we bolstered our leadership team with the addition of an accomplished
10-K/A
mlez2ja
1 May 23
Annual report (amended)
5:12pm
424B4
jz6 zvsbpejos
30 Dec 22
Prospectus supplement with pricing info
4:17pm
FWP
upni84fa g4d959w5
6 Dec 22
Free writing prospectus
4:17pm
S-1/A
d80yl e0f328f
5 Dec 22
IPO registration (amended)
8:16am
S-1
dszxg
18 Nov 22
IPO registration
5:06pm
DRS/A
qh3h33 rxs
28 Oct 22
Draft registration statement (amended)
12:00am
DRS/A
fb7yq1hib1vry jq2g
7 Oct 22
Draft registration statement (amended)
12:00am
DRS
tpjaknsa
19 Aug 22
Draft registration statement
12:00am
- Prev
- 1
- Next